British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011

Br J Dermatol. 2011 Oct;165(4):711-34. doi: 10.1111/j.1365-2133.2011.10575.x.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Adult
  • Aged
  • Azathioprine / adverse effects
  • Azathioprine / metabolism
  • Azathioprine / therapeutic use*
  • Bone Marrow Diseases / chemically induced
  • Chemical and Drug Induced Liver Injury / etiology
  • Chemical and Drug Induced Liver Injury / therapy
  • Child
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Drug Approval
  • Drug Costs
  • Drug Hypersensitivity / etiology
  • Drug Interactions
  • Female
  • Genetic Testing
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / metabolism
  • Immunosuppressive Agents / therapeutic use*
  • Infections / chemically induced
  • Kidney Diseases / complications
  • Lactation
  • Male
  • Methyltransferases / metabolism
  • Nausea / chemically induced
  • Nausea / therapy
  • Neoplasms / chemically induced
  • Off-Label Use
  • Patient Education as Topic
  • Pregnancy
  • Risk Factors
  • Skin Diseases / drug therapy*
  • Thioguanine / metabolism
  • Virus Diseases / complications

Substances

  • Immunosuppressive Agents
  • Methyltransferases
  • thiopurine methyltransferase
  • Thioguanine
  • Azathioprine